A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Clinical trial NCT07529535 · SUSPENDED

Trial details

NCT number: NCT07529535
Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd.
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

Advance Solid Tumors

Start date: 2025-06-05
Primary completion: 2026-12-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.